Matsushita H, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482(7385):400–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schreiber RD, et al. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–70.

Article  CAS  PubMed  Google Scholar 

Kakavand H, et al. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. Pathology. 2016;48(2):194–202.

Article  CAS  PubMed  Google Scholar 

Joshi SS, et al. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264–79.

Article  PubMed  PubMed Central  Google Scholar 

Herbst RS, et al. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–54.

Article  CAS  PubMed  Google Scholar 

Emens LA et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021;9(8).

Topalian SL et al. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367(6477).

Hinshaw DC, et al. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alsaab HO, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.

Article  PubMed  PubMed Central  Google Scholar 

Wu Y, et al. PD-L1 Distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front Immunol. 2019;10:2022.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berry S, et al. Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma. Oncoimmunology. 2015;4(10):e1029704.

Article  PubMed  PubMed Central  Google Scholar 

Yuan Y, et al. Recent advancements in the mechanisms underlying resistance to PD-1/PD-L1 Blockade Immunotherapy. Cancers (Basel). 2021;13(4):663.

Article  CAS  PubMed  Google Scholar 

Hargadon KM, et al. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29–39.

Article  CAS  PubMed  Google Scholar 

Bagchi S, et al. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223–49.

Article  CAS  PubMed  Google Scholar 

Qian W, et al. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target. J Hematol Oncol. 2021;14(1):147.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang J, et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell. 2019;176(1–2):334-47 e12.

Article  CAS  PubMed  Google Scholar 

Maruhashi T, et al. Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity. Immunity. 2022;55(5):912-24 e8.

Article  CAS  PubMed  Google Scholar 

Hirayasu K, et al. Functional and genetic diversity of leukocyte immunoglobulin-like receptor and implication for disease associations. J Hum Genet. 2015;60(11):703–8.

Article  CAS  PubMed  Google Scholar 

Stahl M, et al. Immune checkpoint inhibitors in acute myeloid leukemia: novel combinations and therapeutic targets. Curr Oncol Rep. 2019;21(4):37.

Article  PubMed  Google Scholar 

Deng M, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562(7728):605–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharma N, et al. LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. J Exp Med. 2021;218(7):e20201811.

Inui M, et al. Tolerogenic immunoreceptor ILT3/LILRB4 paradoxically marks pathogenic auto-antibody-producing plasmablasts and plasma cells in non-treated SLE. Int Immunol. 2016;28(12):597–604.

Article  CAS  PubMed  Google Scholar 

Sugahara-Tobinai A, et al. Augmented ILT3/LILRB4 expression of peripheral blood antibody secreting cells in the acute phase of Kawasaki disease. Pediatr Infect Dis J. 2019;38(4):431–8.

Article  PubMed  Google Scholar 

Thies A, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol. 2002;20(10):2530–6.

Article  CAS  PubMed  Google Scholar 

Huang YH, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2015;517(7534):386-U566.

Article  CAS  PubMed  Google Scholar 

Liu S, et al. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021;14(1):7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Markel G, et al. CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol. 2002;168(6):2803–10.

Article  CAS  PubMed  Google Scholar 

Chen Z, et al. CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells. J Exp Med. 2011;208(13):2633–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hirota T, et al. Transcriptional activation of the mouse Necl-5/Tage4/PVR/CD155 gene by fibroblast growth factor or oncogenic Ras through the Raf-MEK-ERK-AP-1 pathway. Oncogene. 2005;24(13):2229–35.

Article  CAS  PubMed  Google Scholar 

Casado JG, et al. Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. Cancer Immunol Immunother. 2009;58(9):1517–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ozmadenci D, et al. Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis. Proc Natl Acad Sci USA. 2022;119(17): e2117065119.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishiwada S, et al. Clinical significance of CD155 expression in human pancreatic cancer. Anticancer Res. 2015;35(4):2287–97.

CAS  PubMed  Google Scholar 

Nakai R, et al. Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma. Cancer Sci. 2010;101(5):1326–30.

Article  CAS  PubMed  Google Scholar 

Iguchi-Manaka A, et al. Increased soluble CD155 in the serum of cancer patients. PLoS ONE. 2016;11(4): e0152982.

Article  PubMed  PubMed Central  Google Scholar 

Curley J, et al. Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia. Mod Pathol. 2020;33(6):1182–92.

Article  CAS  PubMed  Google Scholar 

Demerle C, et al. BTLA-HVEM couple in health and diseases: insights for immunotherapy in lung cancer. Front Oncol. 2021;11: 682007.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu X, et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature. 2020;588(7839):693–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Su M, et al. ERMAP is a B7 family-related molecule that negatively regulates T cell and macrophage responses. Cell Mol Immunol. 2021;18(8):1920–33.

Article  CAS  PubMed  Google Scholar 

Xiang J, et al. Disruption of SIRT7 increases the efficacy of checkpoint inhibitor via mef2d regulation of programmed cell death 1 ligand 1 in hepatocellular carcinoma cells. Gastroenterology. 2020;158(3):664-78 e24.

Article  CAS  PubMed  Google Scholar 

Srivastava PK. Neoepitopes of cancers: looking back, looking ahead. Cancer Immunol Res. 2015;3(9):969–77.

Article